MX2020012895A - Modificacion de linfocitos b al utilizar citidina desaminasa inducida por activacion endogena. - Google Patents
Modificacion de linfocitos b al utilizar citidina desaminasa inducida por activacion endogena.Info
- Publication number
- MX2020012895A MX2020012895A MX2020012895A MX2020012895A MX2020012895A MX 2020012895 A MX2020012895 A MX 2020012895A MX 2020012895 A MX2020012895 A MX 2020012895A MX 2020012895 A MX2020012895 A MX 2020012895A MX 2020012895 A MX2020012895 A MX 2020012895A
- Authority
- MX
- Mexico
- Prior art keywords
- lymphocytes
- engineering
- cytidine deaminase
- induced cytidine
- engineered
- Prior art date
Links
- 210000003719 b-lymphocyte Anatomy 0.000 title abstract 7
- 102100022433 Single-stranded DNA cytosine deaminase Human genes 0.000 title abstract 2
- 101710143275 Single-stranded DNA cytosine deaminase Proteins 0.000 title abstract 2
- 230000005966 endogenous activation Effects 0.000 title 1
- 101710163270 Nuclease Proteins 0.000 abstract 2
- 238000002659 cell therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4612—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4633—Antibodies or T cell engagers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04005—Cytidine deaminase (3.5.4.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona un método para modificar linfocitos B al utilizar citidina desaminasa inducida por activación del linfocito B. De esta manera, el uso de las nucleasas modificadas, tal como Cas nucleasa, se puede evitar. Las células B modificadas son útiles para producir anticuerpos personalizados y para terapia de células B. Por consiguiente, la presente invención también proporciona células B modificadas y anticuerpos personalizados producidos por las células B modificadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2018064299 | 2018-05-30 | ||
PCT/EP2019/064109 WO2019229193A1 (en) | 2018-05-30 | 2019-05-29 | Engineering b lymphocytes by utilizing endogenous activation-induced cytidine deaminase |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020012895A true MX2020012895A (es) | 2021-05-27 |
Family
ID=62620827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020012895A MX2020012895A (es) | 2018-05-30 | 2019-05-29 | Modificacion de linfocitos b al utilizar citidina desaminasa inducida por activacion endogena. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210254106A1 (es) |
EP (1) | EP3802841A1 (es) |
JP (1) | JP2021525517A (es) |
KR (1) | KR20210016446A (es) |
CN (1) | CN112384627A (es) |
AU (1) | AU2019276261A1 (es) |
BR (1) | BR112020024354A2 (es) |
CA (1) | CA3100112A1 (es) |
EA (1) | EA202092807A1 (es) |
MX (1) | MX2020012895A (es) |
SG (1) | SG11202011280SA (es) |
WO (1) | WO2019229193A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114181901B (zh) * | 2021-12-08 | 2024-02-02 | 杭州中赢生物医疗科技有限公司 | 一种免疫细胞的体外诱导扩增和冻存的方法 |
WO2023220206A2 (en) * | 2022-05-10 | 2023-11-16 | Editas Medicine, Inc. | Genome editing of b cells |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
FR2726003B1 (fr) | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires |
DE69729839T2 (de) | 1996-11-12 | 2005-07-21 | Pfizer Inc. | Attenuierter lebender Neospora Impfstoff |
FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
PL1646715T3 (pl) | 2003-07-22 | 2010-10-29 | Valneva | Wytwarzanie pokswirusów za pomocą linii adherentnych lub nieadherentnych komórek ptasich |
US8326547B2 (en) | 2009-10-07 | 2012-12-04 | Nanjingjinsirui Science & Technology Biology Corp. | Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm |
WO2012063048A1 (en) * | 2010-11-08 | 2012-05-18 | Kymab Limited | Cells & vertebrates for enhanced somatic hypermutation and class switch recombination |
EP2927227A4 (en) | 2013-01-03 | 2015-12-30 | Celltrion Inc | ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH |
ES2959608T3 (es) | 2015-04-03 | 2024-02-27 | Dana Farber Cancer Inst Inc | Composición y métodos de edición del genoma de células B |
US20180179274A1 (en) | 2015-06-26 | 2018-06-28 | Institute For Research In Biomedicine | Proteins comprising a mutated lair-1 fragment and uses thereof |
EA201890640A1 (ru) * | 2015-09-04 | 2018-09-28 | Токаджен Инк. | Рекомбинантные векторы, содержащие пептид 2а |
WO2019024979A1 (en) | 2017-07-31 | 2019-02-07 | Institute For Research In Biomedicine | FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION |
-
2019
- 2019-05-29 EP EP19730275.5A patent/EP3802841A1/en active Pending
- 2019-05-29 CN CN201980046344.7A patent/CN112384627A/zh active Pending
- 2019-05-29 SG SG11202011280SA patent/SG11202011280SA/en unknown
- 2019-05-29 EA EA202092807A patent/EA202092807A1/ru unknown
- 2019-05-29 WO PCT/EP2019/064109 patent/WO2019229193A1/en unknown
- 2019-05-29 CA CA3100112A patent/CA3100112A1/en active Pending
- 2019-05-29 AU AU2019276261A patent/AU2019276261A1/en active Pending
- 2019-05-29 MX MX2020012895A patent/MX2020012895A/es unknown
- 2019-05-29 KR KR1020207038076A patent/KR20210016446A/ko unknown
- 2019-05-29 JP JP2020566612A patent/JP2021525517A/ja active Pending
- 2019-05-29 US US17/059,112 patent/US20210254106A1/en active Pending
- 2019-05-29 BR BR112020024354-0A patent/BR112020024354A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019276261A1 (en) | 2020-12-03 |
SG11202011280SA (en) | 2020-12-30 |
EP3802841A1 (en) | 2021-04-14 |
JP2021525517A (ja) | 2021-09-27 |
CN112384627A (zh) | 2021-02-19 |
BR112020024354A2 (pt) | 2021-03-02 |
EA202092807A1 (ru) | 2021-04-08 |
CA3100112A1 (en) | 2019-12-05 |
WO2019229193A1 (en) | 2019-12-05 |
KR20210016446A (ko) | 2021-02-15 |
US20210254106A1 (en) | 2021-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020201465A1 (en) | Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing | |
AU2017335890B2 (en) | RNA-guided nucleic acid modifying enzymes and methods of use thereof | |
SG10201906070XA (en) | Compositions and methods for high efficiency in vivo genome editing | |
PH12019500281A1 (en) | Regulation of gene expression using engineered nucleases | |
NZ765695A (en) | Immune cell organoid co-cultures | |
MX2019003616A (es) | Celulas beta derivadas de celulas madre (sc-beta) y composiciones y metodos para generarlas. | |
GB2542653A (en) | Methods and compositions for treating cells for transplant | |
MX2019011040A (es) | Composiciones y metodos para potenciar la expresion genica. | |
MX2017010746A (es) | Composicion y metodos para la expresion regulada de un complejo de arn guia/endonucleasa cas. | |
MX2018002339A (es) | Composiciones y metodos de mejora de la especificidad en ingenieria genomica usando endonucleasas guiadas por arn. | |
MY197877A (en) | Rna-guided transcriptional regulation | |
MX2023006566A (es) | Sistemas crispr tipo v clase 2 diseñados por ingeniería. | |
PH12015502039B1 (en) | Anti-lag-3 binding proteins | |
SG10201807208RA (en) | Viral resistant cells and uses thereof | |
MX2021005021A (es) | Proceso para producir celulas t geneticamente modificadas. | |
EP4282869A3 (en) | Lithium-ion battery electrolyte and lithium-ion battery | |
EA201890079A1 (ru) | Клеточная система для направленной доставки активного ингредиента | |
EP3752602A4 (en) | METHOD OF GENERATING CELLS OF THE T CELL LINE | |
MX2022006444A (es) | Linfocitos t activados por bite ex vivo. | |
MX2020003339A (es) | Arn guía de cpf1 modificado. | |
WO2016164896A3 (en) | Modulation of smn expression | |
MY192824A (en) | Compound targeting il-23a and tnf-alpha and uses thereof | |
MX2020006494A (es) | Anticuerpos de cadena pesada que se unen a cd22. | |
BR112017017886A2 (pt) | gerando populações de células endoteliais arteriais | |
MY184126A (en) | Transposon system, kit comprising the same, and uses thereof |